, Tracking Stock Market Picks
Enter Symbol:
Conceptus, Inc. (CPTS) [hlAlert]

down 43.71 %

Conceptus, Inc. (CPTS) downgraded to Sell by UBS

Posted on: Tuesday,  Aug 19, 2008  8:25 AM ET by UBS

UBS rated Sell Conceptus, Inc. (NASDAQ: CPTS) on 08/19/2008, when the stock price was $17.46. Since
then, Conceptus, Inc. has gained 77.66% as of 06/05/2014's recent price of $31.02.
If you would have followed this UBS's recommendation on CPTS, you would have lost 43.71% of your investment in 2116 days.

Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing benign tissue in-growth that blocks the fallopian tubes. A properly placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. On January 7, 2008, the Company acquired all of the outstanding shares of Conceptus SAS. Through Conceptus SAS, it sells Essure directly in France and uses distributors to sell Essure throughout the rest of Europe.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/19/2008 8:25 AM Sell
as of 12/24/2008
1 Week down  -9.41 %
1 Month down  -19.01 %
3 Months up  0.14 %
1 YTD up  9.13 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/15/2008 9:25 AM Hold
15.94 19.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy